跳至主要内容
临床试验/TCTR20210326006
TCTR20210326006进行中(未招募)2 期

A double-blind randomized placebo-controlled study of Desvenlafaxine for managing vasomotor symptoms in breast cancer survivors

Khon Kaen University0 个研究点目标入组 60 人开始时间: 2021年3月26日最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
40 Years 至 60 Years(—)
性别
Female

入选标准

  • Women, who were diagnosed breast cancer, have moderate to severe vasomotor symptoms

排除标准

  • 1. Allergy to SSRI and SNRI
  • 2. Hormonal treatment within 4 weeks prior
  • 3. History of epilepsy
  • 4. History of myocardial infarction within 6 months prior
  • 5. History of depression, bipolar disease or psychological conditions
  • 6. History of glaucoma or increased intraocular pressure
  • 7. Malabsorption
  • 8. Hypertension
  • 9. Impaired liver or renal disease

研究者

相似试验

A double-blind randomized placebo-controlled study... | 临床试验